Development of a Microparticulate Prostate Cancer Vaccine and Evaluating the Effect of Route of Administration on its Efficacy via the Skin
The skin has been identified as a promising target to deliver vaccines. In this study, prostate cancer antigens were delivered in a spray-dried microparticulate carrier to a murine model via the transdermal route and the subcutaneous route. There was a significant increase in the humoral responses as determined by the total serum IgG titres (p50.05) and the cellular responses as determined by the T- and B-cells sub-population in spleen samples and delay in tumour growth till 8 weeks post-tumour challenge of both vaccinated groups when compared to the controls. The vaccine microparticles administered via the transdermal route induced a Th2-mediated immune response versus a mixed Th1- and Th2-mediated immune response via the subcutaneous route. Thus, the particulate vaccine delivery system proves to be a promising alternative for generation of a robust immune response against prostate cancer via the skin in a murine model.
Akalkotkar, Archana; Chablani, Lipika; Tawde, Suprita A.; D'Souza, Cherilyn; and D'Souza, Martin J. (2015). "Development of a Microparticulate Prostate Cancer Vaccine and Evaluating the Effect of Route of Administration on its Efficacy via the Skin." Journal of Microencapsulation 32.3, 281-289.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.